Evidence map›Paper›PMID 39969054›Full record

SynthesisActa neuropsychiatrica2025

A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.

Yang Jing Zheng, Crystaleene Soegiharto, Hezekiah C T Au, Kyle Valentino, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Hernan F Guillen-Burgos, Bing Cao and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta neuropsychiatrica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Observational
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yang Jing ZhengBrain and Cognition Discovery Foundation, Toronto, ON, Canada.ORCID https://orcid.org/0009-0001-3238-696X
Crystaleene SoegihartoBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Hezekiah C T AuBrain and Cognition Discovery Foundation, Toronto, ON, Canada.ORCID https://orcid.org/0009-0002-8786-1550
Kyle ValentinoBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Gia Han LeBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Sabrina WongBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Kayla M TeopizBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Taeho Greg RheeDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Hernan F Guillen-BurgosUniversidad El Bosque, Faculty of Medicine, Center for Clinical and Translational Research, Bogota, DC, Colombia.
Bing CaoKey Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, P. R. China.
Roger S McIntyreDepartment of Psychiatry, University of Toronto, ON, Canada.ORCID https://orcid.org/0000-0003-4733-2523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExtant literature implicates the role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) on modulating alcohol-associated behaviours, with a particular emphasis of these agents on neural circuits subserving reward and appetite control. Herein, we explore the potential effects of GLP-1RAs on alcohol-associated behaviours in brain regions implicated in reward processing facilitating the repurposing of these agents for the treatment and prevention of problematic drinking. Understanding how GLP-1's analogues interact with alcohol-related behaviours may underscore the development of therapeutic strategies for alcohol use disorder (AUD) and those with comorbid metabolic disorders.

methodsA systematic review was conducted, wherein relevant literature was identified through Web of Science, PubMed, and OVID (MedLINE, Embase, AMED, PsycInfo, JBI EBP) from database inception to October 27th, 2024. Preclinical and clinical studies examining the association between GLP-1RAs and alcohol-related behaviours were assessed.

resultsPreclinical studies ( DISCUSSION: Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.

Indexed as

AlcoholismGlucagon-Like Peptide-1 Receptor AgonistsAlcohol DrinkingAnimalsExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHumansLiraglutideRewardSemaglutideExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesLiraglutideSemaglutideAlcohol consumptionAlcohol use disorderBipolar disorderDepressionDulaglutideExenatideGLP-1LiraglutideSemaglutide

Identifiers

PMID39969054
PMCPMC13130248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.